A team of BioNTech alumni thinks cancer screening has been stuck in the past, and it has raised $25M to do something about it. Bios Life has emerged from stealth with a plan to replace one-off screening with continuous, AI-driven surveillance, and a data alliance with Tempus to power it. The seed round is well […]This story continues at The Next Web